The past month has seen a growing number of US politicians and legislators crying foul at the practice of inverting. President Obama has described inverters as “fleeing the country to get out of paying taxes”, while Jacob Lew, US Treasury Secretary, has called for a greater sense of “economic patriotism”. Democrats are more adamant about curbing the restructuring technique immediately, while Republicans, for the most part, want to see action under the umbrella of comprehensive tax reform. Sander Levin, his brother Carl, and Ron Wyden, Senate Finance Committee chairman, are among those to have proposed specific anti-inversion legislation, including legislation that would have retrospective effect to May 8 2014. Efforts to reform the US tax code indicate the crawling pace of change on Capitol Hill, but there is no denying there is a narrowing window of opportunity for taxpayers already looking at restructuring, or considering a merger or acquisition, to think about inverting.
Check out our infographic on page 5 to see how pharmaceuticals companies are leading the inversions charge, and review our insights as to which company in the sector could be next to invert.Tweet this #inversionsITR LinkedIn group
July 18 2014
July 4 2014
July 18 2014
|Download this special report as a PDF|
- Inversions: The trend turning transactional tax planning upside down
- US lawmakers call for greater economic patriotism as inversions continue
- Controversial inversions driven by lack of US tax reform
- AstraZeneca's Ian Brimicombe discusses its global transfer pricing strategy
- Pharma and Irish inversions: Increasing your share price
- Why do publicly-traded companies like Ireland?
- Anti-inversion Bills and inbound acquisitions
- New Treasury regulations could affect foreign acquisitions of US corporations
- UK: Moving up the chain as the first choice for tax residency
- Pfizer and AstraZeneca go separate ways...for now
© 2019 Euromoney Institutional Investor PLC. For help please see our FAQ.